Plunkett Research Online: AVEO Pharmaceuticals Inc

AVEO PHARMACEUTICALS INC (AVEO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company that seeks to advance targeted medicines for oncology and other unmet medical needs. AVEO’s lead candidate is tivozanib, which the firm is working to develop and commercialize in North America as a treatment for advanced or metastatic renal .....



AVEO Pharmaceuticals Inc
Ticker: AVEO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617 299-5000
Fax:
Address: One Broadway
14th Floor
Cambridge, MA 02142 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Drugs (Pharmaceuticals), Discovery & Manufacturing
ContactsDescription

Michael BaileyCEO/Director/President
Matthew DallasCFO/Chief Accounting Officer
See More
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company that seeks to advance targeted medicines for oncology and other unmet medical needs. AVEO’s lead candidate is tivozanib, which the firm is working to develop and commercialize in North America as a treatment for advanced or metastatic renal .....See More See More

Auditor: Ernst & Young LLP
Legal Advisor: Wilmer Cutler Pickering Hale and Dorr LLP
$USD, In whole numbers,
except marked * or %
201820172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Tivozanib
FOTIVDA
AV-203
AV-380
AV-353
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: